Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era

The current study reviews chronologic changes in the long term outcome of patients with metastatic nonseminomatous testicular germ cell tumors (NSTGCT) who were treated at a single institution during the past two decades. The 10‐year survival of prognostic subgroups according to the classification of the International Germ Cell Consensus Classification Group (IGCCCG) and various other prognostic classifications is examined in time to evaluate whether cumulative experience has led to an improved outcome of patients with metastatic NSTGCT and to explore differences in outcome of prognostic subgroups.

[1]  J. Richie,et al.  The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985–1996 , 1999, Cancer.

[2]  C. Meisner,et al.  First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Sijmons,et al.  Geographic clustering of testicular cancer incidence in the northern part of The Netherlands , 1999, British Journal of Cancer.

[4]  Sonneveld,et al.  The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996 , 1999, BJU international.

[5]  L. Collette,et al.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.

[6]  E. Feuer,et al.  Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. , 1999, Journal of the National Cancer Institute.

[7]  L. Einhorn,et al.  Advanced testicular cancer: update for urologists. , 1998, The Journal of urology.

[8]  W. Molenaar,et al.  Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. , 1998, Cancer.

[9]  D. Dearnaley,et al.  Markers and management of germ-cell tumours of the testes , 1998, The Lancet.

[10]  L. Collette,et al.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. , 1998, British Journal of Cancer.

[11]  H. Hoekstra,et al.  Current concepts about testicular cancer. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  W. Molenaar,et al.  Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors , 1998 .

[13]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Collette,et al.  Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Fosså,et al.  Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[17]  W. Wilmanns,et al.  Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. , 1996, British Journal of Cancer.

[18]  H. Hoekstra,et al.  The sexual sequelae of testicular cancer. , 1995, Cancer treatment reviews.

[19]  R. Sylvester,et al.  Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. , 1995, British Journal of Cancer.

[20]  J. Habbema,et al.  Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. , 1993, British Journal of Cancer.

[21]  S. Kaye,et al.  Management of malignant teratoma: does referral to a specialist unit matter? , 1993, The Lancet.

[22]  G. Peters,et al.  Modulation of fluorouracil toxicity with uridine. , 1992, Seminars in oncology.

[23]  L. Baldetorp,et al.  Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Newlands,et al.  Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. , 1989, British Journal of Cancer.

[25]  N. Geller,et al.  Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors. , 1988, Cancer research.

[26]  N. Geller,et al.  Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[28]  R. Sylvester,et al.  Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. , 1987, Cancer research.

[29]  L. Einhorn,et al.  Prognostic factors for favorable outcome in disseminated germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[31]  K. Sikora,et al.  PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours , 1985, The Lancet.

[32]  L. Einhorn,et al.  The role of maintenance therapy in disseminated testicular cancer. , 1981, The New England journal of medicine.

[33]  A. Barrett,et al.  COMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS , 1979, The Lancet.

[34]  H. Pinedo,et al.  COMBINATION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO-PLATINUM, VINBLASTINE, AND BLEOMYCIN IN ADVANCED TESTICULAR NON-SEMINOMA , 1979, The Lancet.

[35]  R. Freeman,et al.  Letter: Radioimmunoassay of apo-L.D.L. , 1974, Lancet.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  Daan Brandenbarg.  The National. , 1892 .

[38]  W. Wilmanns,et al.  Late relapse of germ cell tumors after cisplatin-based chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  C. Stiller.  Non-specialist units, clinical trials and survival from testicular cancer. , 1995, European journal of cancer.

[40]  J. Norum,et al.  Testicular cancer treated in a minor general oncology department. , 1995, European journal of cancer.

[41]  A. Horwich,et al.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Motzer,et al.  Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. , 1992, Seminars in oncology.